CTLA4 and melanoma: Co-targeting RANKL and PD-1 effectively inhibits experimental RM1 prostate cancer and B16F10 melanoma metastasis to the lungs and improves the effectiveness of combined anti-CTLA-4 and anti-PD-1 therapy.